Literature DB >> 14682374

Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses.

Giacomo G Vecil1, Frederick F Lang.   

Abstract

Adenoviruses have been critical in the development of the molecular approaches to brain tumors. They have been engineered to function as vectors for delivering therapeutic genes in gene therapy strategies, and as direct cytotoxic agents in oncolytic viral therapies. This review outlines the uses of adenoviruses in brain tumor therapy by examining clinical trials of adenovirus-mediated p53 gene therapy and by reviewing the application of two conditionally replicative adenoviruses (CRAds) ONYX-015 and Delta 24 in brain tumors. The potential clinical use of CRAds that deliver trangenes, particularly p53, is also discussed.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14682374     DOI： 10.1023/b:neon.0000003653.45635.32

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.506


  87 in total

Review 1.  Cancer gene therapy: fringe or cutting edge?

Authors:  F McCormick
Journal:  Nat Rev Cancer       Date:  2001-11       Impact factor: 60.716

2.  A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.

Authors:  I Ganly; D Kirn; G Eckhardt; G I Rodriguez; D S Soutar; R Otto; A G Robertson; O Park; M L Gulley; C Heise; D D Von Hoff; S B Kaye; S G Eckhardt
Journal:  Clin Cancer Res       Date:  2000-03       Impact factor: 12.531

3.  Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.

Authors:  S Mulvihill; R Warren; A Venook; A Adler; B Randlev; C Heise; D Kirn
Journal:  Gene Ther       Date:  2001-02       Impact factor: 5.250

4.  Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration.

Authors:  A Phuangsab; R M Lorence; K W Reichard; M E Peeples; R J Walter
Journal:  Cancer Lett       Date:  2001-10-22       Impact factor: 8.679

5.  Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis.

Authors:  C Gomez-Manzano; J Fueyo; A P Kyritsis; T J McDonnell; P A Steck; V A Levin; W K Yung
Journal:  J Natl Cancer Inst       Date:  1997-07-16       Impact factor: 13.506

6.  Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study.

Authors:  M Schuler; R Herrmann; J L De Greve; A K Stewart; U Gatzemeier; D J Stewart; L Laufman; R Gralla; J Kuball; R Buhl; C P Heussel; F Kommoss; A P Perruchoud; F A Shepherd; M A Fritz; J A Horowitz; C Huber; C Rochlitz
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

7.  Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer.

Authors:  O Wildner; J C Morris; N N Vahanian; H Ford; W J Ramsey; R M Blaese
Journal:  Gene Ther       Date:  1999-01       Impact factor: 5.250

8.  Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.

Authors:  J Nemunaitis; C Cunningham; A Buchanan; A Blackburn; G Edelman; P Maples; G Netto; A Tong; B Randlev; S Olson; D Kirn
Journal:  Gene Ther       Date:  2001-05       Impact factor: 5.250

9.  An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.

Authors:  J R Bischoff; D H Kirn; A Williams; C Heise; S Horn; M Muna; L Ng; J A Nye; A Sampson-Johannes; A Fattaey; F McCormick
Journal:  Science       Date:  1996-10-18       Impact factor: 47.728

10.  Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies.

Authors:  Frederick F Lang; Mark R Gilbert; Vinay K Puduvalli; Jeffrey Weinberg; Victor A Levin; W K Alfred Yung; Raymond Sawaya; Gregory N Fuller; Charles A Conrad
Journal:  Neuro Oncol       Date:  2002-10       Impact factor: 12.300
View more
  33 in total

1.  Negative regulation-resistant p53 variant enhances oncolytic adenoviral gene therapy.

Authors:  Taeyoung Koo; Il-Kyu Choi; Minjung Kim; Jung-Sun Lee; Eonju Oh; Jungho Kim; Chae-Ok Yun
Journal:  Hum Gene Ther       Date:  2012-02-21       Impact factor: 5.695

Review 2.  Novel delivery strategies for glioblastoma.

Authors:  Jiangbing Zhou; Kofi-Buaku Atsina; Benjamin T Himes; Garth W Strohbehn; W Mark Saltzman
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

3.  Cell type- and region-dependent coxsackie adenovirus receptor expression in the central nervous system.

Authors:  Annette Persson; Xiaolong Fan; Bengt Widegren; Elisabet Englund
Journal:  J Neurooncol       Date:  2005-11-29       Impact factor: 4.130

Review 4.  Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Authors:  M J Espy; J R Uhl; L M Sloan; S P Buckwalter; M F Jones; E A Vetter; J D C Yao; N L Wengenack; J E Rosenblatt; F R Cockerill; T F Smith
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 5.  The status of gene therapy for brain tumors.

Authors:  Giulia Fulci; E Antonio Chiocca
Journal:  Expert Opin Biol Ther       Date:  2007-02       Impact factor: 4.388

6.  A Lentiviral Vector Expressing Desired Gene Only in Transduced Cells: An Approach for Suicide Gene Therapy.

Authors:  Zahra Mohammadi; Laleh Shariati; Hossein Khanahmad; Mahsa Kolahdouz; Fariborz Kianpoor; Jahan Afrooz Ghanbari; Zahra Hejazi; Mansoor Salehi; Parvaneh Nikpour; Mohammad Amin Tabatabaiefar
Journal:  Mol Biotechnol       Date:  2015-09       Impact factor: 2.695

Review 7.  Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy.

Authors:  Dayananda Kasala; A-Rum Yoon; Jinwoo Hong; Sung Wan Kim; Chae-Ok Yun
Journal:  Nanomedicine (Lond)       Date:  2016-06-27       Impact factor: 5.307

8.  Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells.

Authors:  Ella L Kim; Robin Wüstenberg; Anne Rübsam; Christoph Schmitz-Salue; Gabriele Warnecke; Eva-Maria Bücker; Nadine Pettkus; Daniel Speidel; Veit Rohde; Walter Schulz-Schaeffer; Wolfgang Deppert; Alf Giese
Journal:  Neuro Oncol       Date:  2010-01-27       Impact factor: 12.300

9.  MiRNA-mediated tumor specific delivery of TRAIL reduced glioma growth.

Authors:  Yongli Bo; Guocai Guo; Weicheng Yao
Journal:  J Neurooncol       Date:  2013-01-22       Impact factor: 4.130

10.  Therapeutic strategies for head and neck cancer based on p53 status.

Authors:  Ichiro Ota; Noritomo Okamoto; Katsunari Yane; Akihisa Takahashi; Takashi Masui; Hiroshi Hosoi; Takeo Ohnishi
Journal:  Exp Ther Med       Date:  2012-02-03       Impact factor: 2.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.